Product Theater – DUPIXENT (dupilumab): Now Approved for an Extended Indication

Featuring Adam Friedman, MD, FAAD Dr. Adam Friedman returned for the afternoon product theater to discuss atopic dermatitis (AD) and treatment with Dupixent. Dupixent is a treatment for moderate to severe atopic dermatitis in patients 12 years of age or older whose disease is not adequately controlled with topical prescription therapies. Dr. Friedman reports “atopic …